



SIGNIFICANT STRATEGIC PARTNERSHIP FOR CHINA DISTRIBUTION IN FINAL STAGES OF NEGOTIATIONS

Respiri Limited (ASX:RSH) today announced that the company is well advanced in negotiations with a major China based pharmaceutical group to optimise the planning and market entry of Respiri into the Chinese market. This party has expressed interest in extending the partnership to include an equity investment in Respiri

China, the Largest Asthma Market in the World

The proposed distribution model for Respiri's products (wheezo™, overnight monitor, stand-alone monitor) will see the large 'China Group' utilise existing channels to complement its existing range of pharmaceutical respiratory products. This distribution network is estimated to include 7,000 - 9,000 hospitals, and some of the group's highest selling products have a direct link with respiratory conditions such as asthma and COPD.

- China is the largest asthma market in the world, with over a 100 million people living with the chronic condition
- Sixteen of the world's pollution hotspots are in China
- There has been a dramatic increase in asthma over the last 20 years; up 40 per cent and rising
- Only 28 per cent of people living with asthma in China have it under control
- Leading cause of hospitalisation in children
- Imposes a huge economic burden for the sufferer and the government
- Air pollution contributed to over 1.2 million deaths in China in 2010

Respiri looks forward to reporting further on these developments once the terms have been finalised and the requisite approvals have been received.

--END--

Contact:
Mario Gattino
CEO & Director
+61 3 9653 9160

Ref: China Daily.com.cn – Study finds little control of asthma – 3 May 2017
TheAtlantic.com – China's asthma problem is bad and growing worse – June 2013

About Respi Limited

Respi's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respi's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respi Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.